Advancing Gene Therapy Development With A Multi-Serotype AAV Resin

Adeno-associated virus (AAV) has emerged as a leading vector for gene delivery for treating various diseases due to its safety profile and efficient transduction of various target tissues. Yet, advances in purification tools and techniques are needed to dependably develop and manufacture high quality AAV. A platform purification process for various AAV serotypes is a crucial step supporting the continued emergence of the commercial gene therapy sector.

In this webinar, leading CDMO ABL and Thermo Fisher will share data on implementation of the POROS™ CaptureSelect™ AAVX affinity resin into such an AAV purification platform, including its performance in purifying several serotypes.

Viewers will learn about:

• Considerations for a platform affinity chromatography step helps to achieve high purity, high yield, and high recovery in AAV production for a variety of serotypes.
• How utilization of the POROS™ CaptureSelect™ AAVX resin can result in significant improvement to the downstream process of AAV
• Advancements in AAV vector purification and insights on future developments in the downstream process of this gene therapy vector.